ArticleIEEE transactions on bio-medical engineering2012
Robust closed-loop minimal sampling method for HIV therapy switching strategies.
Article in IEEE transactions on bio-medical engineering, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression.Cellular and molecular bioengineering · 2020Article
- Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings.PLoS computational biology · 2015Article
- Article
- HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The emergence of drug-resistant strains of human immunodeficiency virus during antiretroviral therapy is a major cause of treatment failure and disease progression. Development of a resistant strain necessitates switching to a new antiretroviral regimen composed of novel drugs. Recent work has shown that current methods of switching antiviral therapies carry significant unnecessary risk of subsequent failures, and optimal switching schedules to minimize this risk have been proposed. These switching schedules require frequent sampling of viral load during an induced phase of transient viral load reduction, with the goal of switching to the new antiviral regimen at an induced viral load minimum. The proposed frequent sampling carries an unacceptable level of cost both in terms of measurement expense and inconvenience to the patient. In this paper, we propose a closed-loop sampling algorithm to reduce the number of samples required to achieve the desired reduction in risk. We demonstrate through the Monte-Carlo analysis that the proposed method is able to robustly achieve an average 50% reduction in the number of required samples while maintaining a reduction in the risk of subsequent failure to under 3%, despite experimentally verified levels of model and measurement uncertainty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.